Journal article
Pregabalin in fibromyalgia--responder analysis from individual patient data.
- Abstract:
-
BACKGROUND: Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but needs validating for level of response and treatment duration. A consensus group has defined what constitutes minimal, moderate, and substantial benefit based on pain intensity and Patient Global Impression of Change scores. METHODS: We obtained individual patient data from four randomised double blind trials of pregabalin in fibromyalgia lasting eight to 14 weeks. We calculat...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 881.7KB, Terms of use)
-
(Version of record, xml, 72.8KB, Terms of use)
-
(Version of record, zip, 1.2MB, Terms of use)
-
- Publisher copy:
- 10.1186/1471-2474-11-150
Authors
Funding
Bibliographic Details
- Publisher:
- BioMed Central
- Journal:
- BMC musculoskeletal disorders More from this journal
- Volume:
- 11
- Issue:
- 1
- Pages:
- 150
- Publication date:
- 2010-01-01
- DOI:
- EISSN:
-
1471-2474
- ISSN:
-
1471-2474
Item Description
- Language:
-
English
- Keywords:
-
- UUID:
-
uuid:dc3b0a45-cdc4-4a52-b046-ef6a769e03e9
- Local pid:
-
pubs:243726
- Source identifiers:
-
243726
- Deposit date:
-
2012-12-19
Terms of use
- Copyright holder:
- Straube et al
- Copyright date:
- 2010
- Notes:
- © 2010 Straube et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record